MedicQuant ApS
Key figures
- Return on assets
- -9.6%
- Return on equity
- -7.4%
- Current ratio
- 593.6%
- Equity ratio
- 87.3%
Profit and loss
| Reporting period | |
|---|---|
Gross profit | 1,911,164 |
Operating profit | -1,098,767 |
Finance income | 32,888 |
Finance expenses | 10,732 |
Tax expense | -334,649 |
Profit/loss for the year | -741,962 |
Employees
| Reporting period | |
|---|---|
Avg. employees | 7 |
Personnel costs | 2,994,376 DKK |
Balance sheet
| Reporting period | |
|---|---|
Cash and cash equivalents | 936,529 |
Current assets | 2,260,546 |
Non-current assets | 9,197,312 |
Total assets | 11,457,858 |
Equity | 10,000,226 |
Liabilities | 1,457,632 |
Current liabilities | 380,797 |
Working capital
| Reporting period | |
|---|---|
Trade receivables | 0 |
Other current receivables | 153,465 |
Trade payables | 71,533 |
Capital and dividend
| Reporting period | |
|---|---|
Contributed capital | 90,839 |
Retained earnings | -9,342,142 |
Investments and assets
| Reporting period | |
|---|---|
Long-term investments and receivables | 120,486 |
Property, plant and equipment | 133,765 |
Annual report highlights
Business and development
Description of key activities of the companyThe purpose of the company is to develop and manufacture medical devices and reagents for in vitro diagnostic purpose.
Significant changes in the company's activities and financial mattersThe gross profit for the year totals DKK 1.911 thousand against DKK 1.094 thousand last year. Profit or loss from ordinary activities after tax totals DKK -742 thousand against DKK -501 thousand last year.
Financial resourcesAs of the balance sheet date, the company does not have sufficient funds to continue the development of its project. During February 2026, Management has however secured in excess of DKK 22 million to support the continued development of the project towards commercialisation. Based on this, management has prepared the financial statements as a going concern.
Risks and material matters
1.
Financial resourcesAs of the balance sheet date, the company does not have sufficient funds to continue the development of its project. During February 2026, Management has however secured in excess of DKK 22 million to support the continued development of the project towards commercialisation. Based on this, management has prepared the financial statements as a going concern.
Events occurring after the end of the financial yearApart from the above, no events have occurred after the balance sheet date of material importance to the annual report for 2025.
Commitments and security
10.Contractual obligations and contingencies, etc.
DKK in thousands…
Create a free account to see up to 9 years of financial history
Create free account